Regorafenib is an oral multi-kinase inhibitor developed by bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (rtk). regorafenib shows anti-angiogenic activity due to its dual targeted vegfr2-tie2 tyrosine kinase inhibition. indications:*metastatic colorectal cancer.*advanced gastrointestinal stromal tumours.